Last Updated: November 7, 2026

Details for Patent: 9,394,283

Name: Drug Patent Intelligence for US Patent 9394283
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,394,283 protect, and when does it expire?

Patent 9,394,283 protects TAZVERIK and is included in one NDA.

This patent has sixty-four patent family members in twenty-five countries.

Summary for Patent: 9,394,283

Title:	Salt form of a human histone methyltransferase EZH2 inhibitor
Abstract:	Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
Inventor(s):	Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Frances Fang
Assignee:	Eisai R&D Management Co Ltd , Epizyme Inc
Application Number:	US14/394,431
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,394,283

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y	Y		METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION	⤷ Start Trial
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial	Y	Y		METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 9,394,283

PCT Information
PCT Filed	April 11, 2013	PCT Application Number:	PCT/US2013/036193
PCT Publication Date:	October 17, 2013	PCT Publication Number:	WO2013/155317

International Family Members for US Patent 9,394,283

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013245878	⤷ Start Trial
Australia	2018200168	⤷ Start Trial
Brazil	112014025508	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.